Dostarlimab｜Endometrial Cancer｜HongKong DengYue Medicine

Dostarlimab Application Scope

• Treatment of recurrent or advanced endometrial cancer with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) after prior platinum-based chemotherapy.
• Approved for dMMR/MSI-H solid tumors, including colorectal cancer (under investigation for locally advanced rectal cancer).

Dostarlimab Characteristics

• Ingredients: Humanized monoclonal anti-PD-1 antibody.
• Properties: Binds to PD-1 with high affinity (IC50: 1.8 nM for PD-L1/PD-1, 1.5 nM for PD-L2/PD-1).
• Specification:
  • 500 mg/vial for initial doses (Q3W)
  • 1000 mg/vial for subsequent doses (Q6W).
• Packaging Specification: Single-dose vials for intravenous infusion.
• Storage: Store at 2–8°C (refrigerated); protect from light.
• Expiry Date: Typically 24 months from manufacture (check specific batch).
• Executive Standard: FDA, EMA, and other regulatory approvals.
• Approval Number: Varies by region (e.g., FDA: BLA 761174).
• Date of Revision: Last updated per regulatory filings (e.g., 2023 for new indications).
• Manufacturer: GlaxoSmithKline (GSK).

Guidelines for the Use of Dostarlimab

Dosage and Administration:

• Initial regimen: 500 mg IV every 3 weeks for 4 doses.
• Maintenance: 1000 mg IV every 6 weeks until disease progression or unacceptable toxicity.
• Infusion time: ≥30 minutes.

Adverse Reactions:

• Common: Fatigue, nausea, diarrhea, anemia, rash, constipation.
• Serious: Immune-related adverse events (pneumonitis, hepatitis, colitis), infusion reactions, endocrine disorders.

Contraindications:

• Hypersensitivity to dostarlimab or excipients.
• Severe autoimmune diseases requiring immunosuppression.

Precautions:

• Monitor for immune-mediated reactions (e.g., pneumonitis, colitis).
• Avoid in pregnancy (use effective contraception for ≥4 months post-treatment).

Dostarlimab Interactions

Drug Interactions:

• No significant interactions reported, but caution with immunosuppressants and live vaccines.

 

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.